Trial Profile

Aflibercept Treatment with Fluoropyrimidine and Irinotecan Starting before radical surgery in patients with Resistant rectal cancer failing to respond or showing disease progression according to magnetic resonance imaging (MRI) criteria at a six weeks assessment after completion of treatment with neoadjuvant chemoradiation to downstage and facilitate a curative resection.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 29 Oct 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary) ; Irinotecan (Primary) ; Fluoropyrimidine derivatives
Indications Adenocarcinoma; Rectal cancer
Focus Therapeutic Use
Acronyms AT FIRST

25 Oct 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by United Kingdom Clinical Research Network record.
11 Jul 2014 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com